Entereg's safety surprise

A slight excess of serious cardiovascular events in patients receiving Entereg alvimopan in a six-month interim review of data from a safety trial prompted FDA to issue a second approvable letter last week asking for 12-month safety data. The problem for Adolor Corp. and partner GlaxoSmithKline plc is that the ongoing trial wasn't designed to answer questions about cardiovascular

Read the full 598 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE